


IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

Last Trade:	6.00
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	0.03  (+0.503%)
Day Range	5.89 - 6.36
52-Week Range	1.51 - 8.84
Volume	3,543,577

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 16, 2017*
[ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active](#)
- Oct 11, 2017*
[ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares](#)
- Oct 5, 2017*
[ImmunoGen Announces Pricing of Public Offering of Common Stock](#)
- Oct 4, 2017*
[ImmunoGen Announces Proposed Public Offering of Common Stock](#)
- Sep 5, 2017*
[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Aug 25, 2016*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)